| 中文摘要 |
大腸直腸癌高居國人癌症死因的第三名，且根據腫瘤發展的病理路徑，大腸直腸癌常合併腹膜腫瘤轉移發生，當疾病復發及轉移後，病人平均存活期約只有6－8個月，常被視為是不可治癒且預後不佳的疾病，多數病人多採取姑息性治療為主，但近年來將腹膜轉移視為是局部－區域性的擴散過程，發展出溫熱式腹內化學治療合併細胞減積手術，術後的五年存活率已大幅改善。本文整理近期大腸直腸癌合併腹膜轉移之病理機轉、溫熱式腹內化學治療及細胞減積手術概念、手術治療過程、術後相關合併症及照護文獻，提升臨床醫護人員對於手術方式及術後照護進一步的認識，提供病人更優質的健康照護。
Colorectal cancer (CRC) is the third leading cause of cancer-related death in Taiwan. According to the pathological pathway of tumors, peritoneum is a frequent site for metastases in colorectal cancer. Once a patient has developed colorectal cancer with peritoneal metastases, survival duration is only approximately 6-8 months. Such disease with poor prognosis is considered incurable; thus, most patients choose palliative therapy for treatment. However, studies in recent years have regarded peritoneal metastases as having local-regional dissemination. Hence, cytoreductive surgery with hyperthermic intraperitoneal chemotherapy has been developed; the 5-year survival rate of this treatment constitutes a considerable improvement. This article summarized the pathogenesis of colorectal cancer with peritoneal metastases, as well as the concept, process, postoperative complications, and patient care of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. This article provided among professionals with further insight regarding the aforementioned surgery and postoperative care, thereby enabling patients to receive more effective health care. |
本站僅提供期刊文獻檢索。
